Skip to main content

Table 2 Echocardiographic parameters and systolic arterial pressure in all dogs, healthy dogs and dogs with different stages of MMVD

From: Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease

  All dogs Healthy Stage B1 Stage B2 Stage C
Number 149 49 45 13 42
LA/Ao 1.42 (1.17–1.89) 1.20 (1.08–1.39) ‡§ 1.26 (1.14–1.43) ‡§ 1.79 ± 0.22 § 2.31 (1.84–2.69)
LVEDDn 1.55 (1.35–1.86) 1.42 ± 0.18 ‡§ 1.39 (1.27–1.63) ‡§ 1.83 ± 0.22 2.00 ± 0.35
LVESDn 0.91 (0.78–1.05) 0.89 ± 0.15 § 0.86 ± 0.18 § 0.96 ± 0.14 1.04 (0.95–1.14)
E peak velocity (m/s) 0.83 (0.65–1.13) 0.67 ± 0.16 ‡§ 0.75 ± 0.17 ‡§ 0.97 ± 0.20 § 1.32 ± 0.32
A peak velocity (m/s) 0.70 (0.55–0.83) 0.59 ± 0.13 ‡§ 0.68 (0.54–0.82) § 0.76 (0.70–0.86) 0.81 (0.70–0.97)
E/A 1.23 (1.00–1.51) 1.17 ± 0.27 § 1.12 ± 0.30 § 1.20 ± 0.26 § 1.66 ± 0.55
SAP 142.94 ± 19.73 145 (140–150) 141.76 ± 20.62 155 (127.50–170) 140.67 ± 20.96
  1. LA/Ao Left atrium-to-aortic root ratio, E/A E peak velocity-to-A peak velocity ratio, LVEDDn Normalized left ventricular end-diastolic diameter, LVESDn Normalized left ventricular end-systolic diameter, SAP Systolic arterial pressure
  2. Data are reported as mean ± standard deviation for normally distributed variables and median (interquartile range) for non-normally distributed variables
  3. †values significantly differ (p < 0.05) from stage B1; ‡values significantly differ (p < 0.05) from stage B2; §values significantly differ (p < 0.05) from stage C